OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart drug mavacamten tested for long-term safety in HCM patients
Disease control CompletedThis study looked at the long-term safety of the drug mavacamten in adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. About 314 people who had already finished earlier studies took part. The goal was to track side effects over time, not to cure…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aficamten shows promise for thick heart muscle in chinese patients
Disease control CompletedThis study tested a drug called aficamten in 40 Chinese patients with a type of heart disease where the heart muscle is too thick and blocks blood flow. The goal was to see if the drug is safe and helps the heart work better over time. Patients who had already been in a similar s…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Corxel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC